Remove Communication Remove Compounding Remove White Paper
article thumbnail

Today's Biomanufacturing Options - Build, Broker, or Blend?

ISPE

Download White Paper To download this white paper, complete the form below. Once submitted, you will receive a link via the email you provided to download the white paper. You may unsubscribe from these ISPE communications at any time. Leave this field blank Product Development ATMPs Biotech

article thumbnail

Utilising content metrics to improve digital engagement

pharmaphorum

Using content metrics, companies can understand how their current content is received and engaged with, which will, in turn, helps clarify the most effective and efficient ways to connect and communicate with their audience in the future, resulting in increased speed to market and effective content engagement.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Online TOC Comparison: Sensors and Analyzers

ISPE

Online TOC Comparison: Sensors and Analyzers Trudy Patterson Wed, 05/03/2023 - 16:00 White Paper — Sponsored Content Online TOC Comparison: Sensors and Analyzers 1 May 2023 This application note shows how TOC analyzers and common sensors in the industry recover 11 different compounds most often used in water and product analysis.

article thumbnail

Today’s Biomanufacturing Options Build, Broker, or Blend

ISPE

With more than 400 registered gene therapy clinical trials worldwide and a compound annual growth rate of more than 25% since 2015, there is no doubting the impact of cell and gene therapy (CGT) innovation on the market. Download White Paper. To download this white paper, complete the form below.

article thumbnail

Boehringer Ingelheim partners with 3T Biosciences for cancer therapies

Pharmaceutical Technology

The collaboration will combine 3T Biosciences’ 3T- T-Cell Receptor Antigen and Cross-Reactivity Engine (TRACE) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining compounds that are directed towards cancer cells and target immune cells.

article thumbnail

A Proposal for a Comprehensive Quality Overall Summary

ISPE

Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a white paper describing the content and format of an improved Module 2. Currently, it takes time and/or communications (e.g., July–August 2020).

article thumbnail

A Proposal for a Comprehensive Quality Overall Summary

ISPE

Ultimately, the summary was not adopted during the QbD pilot, but was reintroduced in 2014 when a Pharmaceutical Research and Manufacturers of America (PhRMA) team prepared a white paper describing the content and format of an improved Module 2. Currently, it takes time and/or communications (e.g., July–August 2020).